Model-assisted process optimization of ion-exchange chromatography for monoclonal antibody charge variant separation

被引：0

作者：

Xu R. ^{[1
]}

Chen Y. ^{[1
]}

Gao D. ^{[2
]}

Jiao J. ^{[2
]}

Gao D. ^{[2
]}

Wang H. ^{[2
]}

Yao S. ^{[1
]}

Lin D. ^{[1
]}

机构：

[1] Key Laboratory of Biomass Chemical Engineering, Ministry of Education, College of Chemical and Biological Engineering, Zhejiang University, Zhejiang, Hangzhou

[2] Hisun Biopharmaceutical Co., Ltd., Zhejiang, Hangzhou

来源：

Huagong Xuebao/CIESC Journal | 2024年 / 75卷 / 05期

关键词：

charge variant; chromatography model; ion-exchange chromatography; monoclonal antibody; process optimization; separation;

D O I：

10.11949/0438-1157.20231246

中图分类号：

学科分类号：

摘要：

For the separation of monoclonal antibody charge heterogeneous species, an ion-exchange chromatography mechanism model is used to predict the elution and separation behavior and assist in the optimization of process conditions. The calibration experiments were designed to estimate the model parameters and the model simulation matched well with the experiments, demonstrating the model has good predictive ability. The model was used to compare and evaluate the influences of different elution modes and conditions. The optimal two-step elution was obtained to achieve high yield. However, it was found that the separation efficiency was highly sensitive to the salt concentration of first-step elution solution. Therefore, the process robustness was considered further to optimize the salt concentration, and it was found the salt concentration of 108.5 mmol/L could greatly enhance the process robustness. The results of validation experiments showed that the highest yield of two-step elution process reached 85.3%, and the operating range of the salt concentration of first-step elution was widened to 98.9—117.5 mmol/L. The results demonstrated that model-assisted process optimization could facilitate the complex condition analysis, promote the optimization and provide reasonable solutions for process robustness. © 2024 Materials China. All rights reserved.

引用

页码：1903 / 1911

页数：8

共 31 条

[1]

Mullard A., FDA approves 100th monoclonal antibody product, Nature Reviews Drug Discovery, 20, pp. 491-495, (2021)

[2]

Fisher A C, Kamga M H, Agarabi C, Et al., The current scientific and regulatory landscape in advancing integrated continuous biopharmaceutical manufacturing, Trends in Biotechnology, 37, 3, pp. 253-267, (2019)

[3]

Kaplon H, Chenoweth A, Crescioli S, Et al., Antibodies to watch in 2022, MAbs, 14, 1, (2022)

[4]

Rathore A S, Winkle H., Quality by design for biopharmaceuticals, Nature Biotechnology, 27, pp. 26-34, (2009)

[5]

Saleh D, Wang G, Rischawy F, Et al., In silico process characterization for biopharmaceutical development following the quality by design concept, Biotechnology Progress, 37, 6, (2021)

[6]

Hong G, Bazin-Redureau M I, Scherrmann J M., Pharmacokinetics and organ distribution of cationized colchicine-specific IgG and Fab fragments in rat, Journal of Pharmaceutical Sciences, 88, 1, pp. 147-153, (1999)

[7]

Chung S, Tian J, Tan Z J, Et al., Industrial bioprocessing perspectives on managing therapeutic protein charge variant profiles, Biotechnology and Bioengineering, 115, 7, pp. 1646-1665, (2018)

[8]

Ahmed S, Atia N N, Rageh A H., Selectivity enhanced cation exchange chromatography for simultaneous determination of peptide variants, Talanta, 199, pp. 347-354, (2019)

[9]

Fekete S, Beck A, Veuthey J L, Et al., Ion-exchange chromatography for the characterization of biopharmaceuticals, Journal of Pharmaceutical and Biomedical Analysis, 113, pp. 43-55, (2015)

[10]

Benner S W, Welsh J P, Rauscher M A, Et al., Prediction of lab and manufacturing scale chromatography performance using mini-columns and mechanistic modeling, Journal of Chromatography. A, 1593, pp. 54-62, (2019)

← 1 2 3 4 →